Repligen Corporation (RGEN)

NasdaqGS Currently down 4.40 (-3.14%) in today's trading session

2 members of Congress have disclosed 7 trades in Repligen Corporation (RGEN) via STOCK Act filings. The most recent disclosure was a sale by Lisa McClain on 31 October 2025. The most active traders have been Lisa McClain (6) and Jefferson Shreve (1). Aggregate disclosed activity totals roughly $24K in purchases and $56.5K in sales (midpoint estimates from bracketed disclosure amounts).

Repligen Corporation is currently trading at $135.69, positioned at 46% of its 52-week range ($100.99 – $175.77).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$135.69
24h Change
-4.40 (-3.14%)
52 Week Range
$100.99$175.77
View on NASDAQ

Repligen Corporation Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for RGEN

Select to highlight on chart
5 transactions
Compliance: 71%
Lisa McClain31 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Lisa McClain30 Oct 202521 Nov 2025SaleStock$1,001 - $15,000N/A
Lisa McClain30 Oct 202521 Nov 2025PurchaseStock$1,001 - $15,000-8.61%
Lisa McClain22 Jul 202513 Aug 2025PurchaseStock$1,001 - $15,000+15.85%
Jefferson Shreve7 Apr 20258 May 2025SaleStock$15,001 - $50,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$7.65B

Volume

1.76M

Beta

1.06

P/E Ratio

75.38

Fundamentals

EPS

$1.80

Div. Yield

Open

$144.23

Day Range

$132.28 — $148.37

Company Information

Sector
Healthcare
Industry
Medical - Instruments & Supplies
Exchange
NASDAQ · USD
Country
US
CEO
Olivier Loeillot
IPO Date
1986-04-29

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe,...

Earnings

Next Report

Q2 2026

28 Jul

EPS Est.

$0.45

Rev. Est.

$201.4M

Days Until

5

Recent Quarters

Q1 20265 May
EPS$0.48
Beat 26.3%
Q4 202524 Feb
EPS$0.49
Beat 11.4%
Q3 202528 Oct
EPS$0.46
Beat 9.5%
Q2 202529 Jul
EPS$0.37
Miss 7.5%
Q1 202529 Apr
EPS$0.39
Beat 11.4%
Q4 202420 Feb
EPS$0.44
Beat 7.3%
Q3 202412 Nov
EPS$0.43
Beat 28.2%
Q2 202430 Jul
EPS$0.33
Beat 0.0%
Q1 20241 May
EPS$0.28
Miss 3.5%
Q4 202321 Feb
EPS$0.33
Miss 2.9%
Q3 202331 Oct
EPS$0.23
Beat 64.3%
Q2 20232 Aug
EPS$0.53
Beat 8.2%
Q1 20232 May
EPS$0.64
Beat 8.5%
Q4 202222 Feb
EPS$0.68
Beat 17.2%
Q3 20221 Nov
EPS$0.77
Beat 13.2%
Q2 20222 Aug
EPS$0.91
Beat 26.4%
Q1 202227 Apr
EPS$0.92
Beat 27.8%
Q4 202117 Feb
EPS$0.81
Beat 24.6%
Q3 202128 Oct
EPS$0.78
Beat 21.9%
Q2 202127 Jul
EPS$0.79
Beat 49.1%
Q1 20214 May
EPS$0.68
Beat 58.1%
Q4 202024 Feb
EPS$0.52
Beat 67.7%
Q3 20205 Nov
EPS$0.40
Beat 42.9%
Q2 202030 Jul
EPS$0.42
Beat 50.0%
Q1 20206 May
EPS$0.32
Beat 45.5%
Q4 201920 Feb
EPS$0.20
Beat 11.1%
Q3 201931 Oct
EPS$0.26
Beat 30.0%
Q2 20191 Aug
EPS$0.31
Beat 24.0%
Q1 20199 May
EPS$0.28
Beat 33.3%
Q4 201821 Feb
EPS$0.21
Beat 0.0%
Q3 20181 Nov
EPS$0.20
Beat 11.1%
Q2 20182 Aug
EPS$0.16
Miss 11.1%
Q1 20188 May
EPS$0.17
Beat 13.3%
Q4 201722 Feb
EPS$0.20
Beat 66.7%
Q3 20179 Nov
EPS$0.15
Beat 36.4%
Q2 20173 Aug
EPS$0.20
Beat 33.3%
Q1 20174 May
EPS$0.15
Beat 15.4%
Q4 201622 Feb
EPS$0.08
Beat 14.3%
Q3 20163 Nov
EPS$0.08
Beat 0.0%
Q2 20164 Aug
EPS$0.16
Beat 23.1%
Q1 20165 May
EPS$0.12
Beat 20.0%
Q4 201525 Feb
EPS$0.01
Miss 87.5%
Q3 20155 Nov
EPS$0.08
Beat 0.0%
Q2 20156 Aug
EPS$0.11
Beat 10.0%
Q1 20157 May
EPS$0.09
Beat 12.5%
Q4 201413 Mar
EPS$-0.01
Miss 125.0%
Q3 20146 Nov
EPS$0.04
Miss 20.0%
Q2 201411 Aug
EPS$0.09
Beat 50.0%
Q1 20148 May
EPS$0.13
Beat 44.4%
Q4 20136 Mar
EPS$0.10
Miss 28.6%
Q3 20137 Nov
EPS$0.18
Beat 38.5%
Q2 20131 Aug
EPS$0.14
Beat 40.0%
Q1 20132 May
EPS$0.07
Miss 36.4%
Q4 20127 Mar
EPS$0.31
Beat 342.9%
Q3 20128 Nov
EPS$0.07
Beat 250.0%
Q2 20122 Aug
EPS$0.05
Q2 20122 Aug
EPS$0.04
Q4 201115 Mar
EPS$-0.07
Q3 201127 Oct
EPS$0.02
Beat 200.0%
Q2 201127 Jul
EPS$-0.00
Beat 82.0%
Q1 20119 Jun
EPS$-0.06
Miss 100.0%
Q4 20109 Feb
EPS$0.01
Beat 133.3%
Q3 20102 Nov
EPS$0.02
Beat 150.0%
Q3 20102 Nov
EPS$0.03
Q1 20109 Jun
EPS$-0.05
Miss 25.0%
Q1 20109 Jun
EPS$-0.01
Q3 20095 Nov
EPS$-0.03
Beat 25.0%
Q2 20096 Aug
EPS$-0.04
Beat 0.0%
Q1 200911 Jun
EPS$-0.09
Miss 50.0%
Q4 20085 Feb
EPS$0.00
Beat 102.0%
Q3 20086 Nov
EPS$0.00
Beat 111.5%
Q2 20087 Aug
EPS$0.26
Beat 62.5%
Q1 200812 Jun
EPS$-0.10
Miss 400.0%
Q4 20077 Feb
EPS$-0.01
Beat 84.4%
Q3 20078 Nov
EPS$1.31
Beat 13200.0%
Q2 20078 Aug
EPS$0.01
Beat 200.0%
Q1 20077 Jun
EPS$-0.00
Beat 82.5%
Q4 20068 Feb
EPS$-0.00
Beat 97.0%
Q3 20062 Nov
EPS$-0.03
Miss 50.0%
Q2 20068 Aug
EPS$0.01
Beat 133.0%
Q1 20068 Jun
EPS$-0.03
Miss 200.0%
Q4 20059 Feb
EPS$-0.01
Beat 66.5%
Q3 20053 Nov
EPS$-0.02
Beat 0.0%
Q2 200527 Jul
EPS$0.07
Beat 333.3%
Q1 200525 May
EPS$-0.01
Beat 64.5%
Q4 20044 Feb
EPS$-0.01
Beat 84.0%
Q3 20049 Nov
EPS$-0.06
Beat 0.0%
Q2 20049 Aug
EPS$-0.02
Beat 50.0%
Q1 200410 Jun
EPS$-0.03
Beat 40.0%
Q4 200311 Feb
EPS$-0.07
Beat 12.5%
Q3 200312 Nov
EPS$-0.07
Miss 40.0%
Q2 200331 Jul
EPS$-0.07
Miss 40.0%
Q1 20035 Jun
EPS$-0.06
Miss 50.0%
Q1 20035 Jun
EPS$-0.03
Q3 200212 Nov
EPS$-0.04
Q2 20022 Aug
EPS$-0.04
Q1 200224 May
EPS$-0.03
Q4 200114 Feb
EPS$-0.03
Q3 200114 Nov
EPS$-0.05
Q2 200114 Aug
EPS$-0.05
Q1 200129 Jun
EPS$-0.06
Q4 200014 Feb
EPS$-0.06
Q3 200014 Nov
EPS$-0.05
Q2 200011 Aug
EPS$-0.04
Q1 200023 Jun
EPS$-0.04
Q4 199914 Feb
EPS$-0.08
Q3 199915 Nov
EPS$-0.04
Q2 199913 Aug
EPS$-0.02
Q1 199929 Jun
EPS$-0.11
Q4 199812 Feb
EPS$-0.02
Q3 199813 Nov
EPS$-0.01
Q2 19987 Aug
EPS$-0.02
Q1 199826 Jun
EPS$-0.02
Q4 199712 Feb
EPS$-0.01
Q3 199713 Nov
EPS$-0.01
Q2 19971 Aug
EPS$-0.01
Q1 19972 Jun
EPS$-0.01
Q4 199613 Feb
EPS$-0.01
Q3 199612 Nov
EPS$0.02
Q1 199627 Jun
EPS$-0.38
Q4 199520 Feb
EPS$-0.15
Q3 199514 Nov
EPS$-0.06
Q2 199516 Aug
EPS$-0.86
Miss 160.6%
Q2 199516 Aug
EPS$-0.87
Q4 199414 Feb
EPS$-0.38
Beat 2.6%
Q3 19941 Nov
EPS$-0.45
Miss 15.4%
Q2 199419 Jul
EPS$-0.39
Beat 2.5%
Q1 19942 Jun
EPS$-0.34
Miss 9.7%
Q4 199314 Feb
EPS$-0.45
Miss 21.6%
Q3 19939 Nov
EPS$-0.38
Beat 0.0%
Q2 199330 Jul
EPS$-0.37
Beat 5.1%
Q1 199319 May
EPS$-0.27
Beat 25.0%
Q4 199212 Feb
EPS$-0.34
Beat 5.6%

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

PLTR

Palantir Technologies Inc.

20
$122.23-2.34 (-1.88%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

TSM

Taiwan Semiconductor Manufacturing Company Limited

20
$415.69-5.52 (-1.31%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

NVDA

NVIDIA Corporation

20
$207.88-4.19 (-1.97%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

Frequently Asked Questions about RGEN

Which members of Congress have traded RGEN?
2 members of Congress have disclosed 7 trades in Repligen Corporation (RGEN) under the STOCK Act. The most active traders are Lisa McClain and Jefferson Shreve.
When was RGEN most recently disclosed by Congress?
The most recent RGEN disclosure was a sale by Lisa McClain on 31 October 2025.
What is the total disclosed congressional trading volume for RGEN?
Members of Congress have disclosed approximately $24K in RGEN purchases and $56.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in RGEN?
This RGEN page updates as soon as new STOCK Act disclosures are filed for Repligen Corporation. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.